Last reviewed · How we verify
NCT06223945
Thrombohemorrhagic Complications of COVID-19
NA trial testing Prevention algorithm in COVID-19 (Coronavirus Disease 2019) in 1 participant. Participants enrolled and being followed up; not accepting new ones.
12 January 2029
Quick facts
| Lead sponsor | Volgograd State Medical University |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 1 |
| Start date | 12 January 2024 |
| Primary completion | 12 January 2029 |
| Estimated completion | 12 January 2029 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Prevention algorithm
Conditions studied
- COVID-19 (Coronavirus Disease 2019) — all drugs for COVID-19 (Coronavirus Disease 2019) →
Sponsor
Volgograd State Medical University
Who can join
Adults 18 to 90, any sex, with COVID-19 (Coronavirus Disease 2019). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The nature of the planned study: The topic is of an applied nature and is aimed at improving the results of comprehensive treatment of patients with COVID-19, the course of whose disease was complicated by thrombotic or hemorrhagic catastrophes. It is planned to analyze the results of treatment of this category of patients based on the work of several centers that provided surgical care to patients with COVID-19 during the pandemic (8 cities). As a result of the analysis, it is planned to develop algorithms for the prevention and treatment of thrombotic and hemorrhagic complications in patients with COVID-19. The proposed study will be multicenter, cohort, retrospective. The purpose of the study: Improvement of treatment results in COVID-19 patients with thrombotic or hemorrhagic complications Scientific novelty: For the first time, as a result of a multicenter study, it is expected to identify the most effective approach to the treatment and prevention of thrombotic and hemorrhagic complications in patients with COVID-19. For the first time, it is planned to develop and put into practice algorithms for the application of the most effective methods of treatment and prevention of thrombohemorrhagic complications of COVID-19.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06223945
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 (Coronavirus Disease 2019)
Currently open trials in the same condition.
- NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
Other Volgograd State Medical University trials
Trials by the same sponsor.
- NCT04244435 — Neuroaxial Prophylaxis for CABG · EARLY_PHASE1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06223945 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Volgograd State Medical University
- Last refreshed: 25 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06223945.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing